<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article" xml:lang="en"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">BMC Cancer</journal-id><journal-id journal-id-type="iso-abbrev">BMC Cancer</journal-id><journal-title-group><journal-title>BMC Cancer</journal-title></journal-title-group><issn pub-type="epub">1471-2407</issn><publisher><publisher-name>BioMed Central</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">24499460</article-id><article-id pub-id-type="pmc">3923729</article-id><article-id pub-id-type="publisher-id">1471-2407-14-67</article-id><article-id pub-id-type="doi">10.1186/1471-2407-14-67</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group></article-categories><title-group><article-title>Feasibility of isometric spinal muscle training in patients with bone metastases under radiation therapy - first results of a randomized pilot trial</article-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes" id="A1"><name><surname>Rief</surname><given-names>Harald</given-names></name><xref ref-type="aff" rid="I1">1</xref><email>harald.rief@med.uni-heidelberg.de</email></contrib><contrib contrib-type="author" id="A2"><name><surname>Omlor</surname><given-names>Georg</given-names></name><xref ref-type="aff" rid="I3">3</xref><email>georg.omlor@med.uni-heidelberg.de</email></contrib><contrib contrib-type="author" id="A3"><name><surname>Akbar</surname><given-names>Michael</given-names></name><xref ref-type="aff" rid="I3">3</xref><email>michael.akbar@med.uni-heidelberg.de</email></contrib><contrib contrib-type="author" id="A4"><name><surname>Welzel</surname><given-names>Thomas</given-names></name><xref ref-type="aff" rid="I1">1</xref><email>thomas.welzel@med.uni-heidelberg.de</email></contrib><contrib contrib-type="author" id="A5"><name><surname>Bruckner</surname><given-names>Thomas</given-names></name><xref ref-type="aff" rid="I2">2</xref><email>bruckner@imbi.uni-heidelberg.de</email></contrib><contrib contrib-type="author" id="A6"><name><surname>Rieken</surname><given-names>Stefan</given-names></name><xref ref-type="aff" rid="I1">1</xref><email>stefan.rieken@med.uni-heidelberg.de</email></contrib><contrib contrib-type="author" id="A7"><name><surname>Haefner</surname><given-names>Matthias F</given-names></name><xref ref-type="aff" rid="I1">1</xref><email>matthias.haefner@med.uni-heidelberg.de</email></contrib><contrib contrib-type="author" id="A8"><name><surname>Schlampp</surname><given-names>Ingmar</given-names></name><xref ref-type="aff" rid="I1">1</xref><email>ingmar.schlampp@med.uni-heidelberg.de</email></contrib><contrib contrib-type="author" id="A9"><name><surname>Gioules</surname><given-names>Alexandros</given-names></name><xref ref-type="aff" rid="I1">1</xref><email>alexandros.gioules@med.uni-heidelberg.de</email></contrib><contrib contrib-type="author" id="A10"><name><surname>Habermehl</surname><given-names>Daniel</given-names></name><xref ref-type="aff" rid="I1">1</xref><email>daniel.habermehl@med.uni-heidelberg.de</email></contrib><contrib contrib-type="author" id="A11"><name><surname>von Nettelbladt</surname><given-names>Friedbert</given-names></name><xref ref-type="aff" rid="I1">1</xref><email>friedbert.nettelbladt@med.uni-heidelberg.de</email></contrib><contrib contrib-type="author" id="A12"><name><surname>Debus</surname><given-names>J&#x000fc;rgen</given-names></name><xref ref-type="aff" rid="I1">1</xref><email>juergen.debus@med.uni-heidelberg.de</email></contrib></contrib-group><aff id="I1"><label>1</label>Department of Radiation Oncology, University Hospital of Heidelberg, Im Neuenheimer Feld 400, 69120 Heidelberg, Germany</aff><aff id="I2"><label>2</label>Department of Medical Biometry, University Hospital of Heidelberg, Im Neuenheimer Feld 305, 69120 Heidelberg, Germany</aff><aff id="I3"><label>3</label>Department of Orthopaedics and Trauma Surgery, University Hospital of Heidelberg, Schlierbacherstrasse 120a, 69118 Heidelberg, Germany</aff><pub-date pub-type="collection"><year>2014</year></pub-date><pub-date pub-type="epub"><day>5</day><month>2</month><year>2014</year></pub-date><volume>14</volume><fpage>67</fpage><lpage>67</lpage><history><date date-type="received"><day>26</day><month>8</month><year>2013</year></date><date date-type="accepted"><day>29</day><month>1</month><year>2014</year></date></history><permissions><copyright-statement>Copyright &#x000a9; 2014 Rief et al.; licensee BioMed Central Ltd.</copyright-statement><copyright-year>2014</copyright-year><copyright-holder>Rief et al.; licensee BioMed Central Ltd.</copyright-holder><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by/2.0"><license-p>This is an open access article distributed under the terms of the Creative Commons Attribution License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/2.0">http://creativecommons.org/licenses/by/2.0</ext-link>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.</license-p></license></permissions><self-uri xlink:href="http://www.biomedcentral.com/1471-2407/14/67"/><abstract><sec><title>Background</title><p>Spinal bone metastases are commonly diagnosed in cancer patients. The consequences are pain both at rest and under exercise, impairment of activities of daily life (ADL), reduced clinical performance, the risk of pathological fractures, and neurological deficits. The aim of this randomized, controlled pilot trial was to investigate the feasibility of muscle-training exercises in patients with spinal bone metastases under radiotherapy. Secondary endpoints were local control, pain response and survival.</p></sec><sec><title>Methods</title><p>This study was a prospective, randomized, monocentre, controlled explorative intervention trial to determine the multidimensional effects of exercises for strengthening the paravertebral muscles. On the days of radiation treatment, patients in the control group were physically treated in form of respiratory therapy. Sixty patients were randomized between September 2011 and March 2013 into one of the two groups: differentiated resistance training or physical measure with thirty patients in each group.</p></sec><sec><title>Results</title><p>The resistance training of the paravertebral muscles was feasible in 83.3% of patients (n&#x02009;=&#x02009;25). Five patients died during the first three months. The exercise group experienced no measurable side effects. &#x0201c;Chair stand test&#x0201d; in the intervention group was significant enhanced with additionally improved analgesic efficiency. Patients in intervention group improved in pain score (VAS, 0&#x02013;10) over the course (p&#x02009;&#x0003c;&#x02009;.001), and was significant better between groups (p&#x02009;=&#x02009;.003) after 3&#x000a0;months. The overall pain response showed no significant difference between groups (p&#x02009;=&#x02009;.158) There was no significant difference in overall and bone survival (survival from first diagnosed bone metastases to death).</p></sec><sec><title>Conclusions</title><p>Our trial demonstrated safety and feasibility of an isometric resistance training in patients with spinal bone metastases. The results offer a rationale for future large controlled investigations to confirm these findings.</p></sec><sec><title>Trial registration</title><p>Clinical trial identifier
<ext-link ext-link-type="uri" xlink:href="http://www.clinicaltrials.gov/">NCT01409720</ext-link>.</p></sec></abstract><kwd-group><kwd>Bone metastases</kwd><kwd>Spine</kwd><kwd>Physical exercise</kwd><kwd>Stability</kwd><kwd>Isometric training</kwd></kwd-group></article-meta></front><body><sec><title>Background</title><p>The vertebral column is the main localization of bone metastases, where they frequently indicate an advanced stage of a malignant primary disease
[<xref ref-type="bibr" rid="B1">1</xref>,<xref ref-type="bibr" rid="B2">2</xref>]. Two thirds of all tumor patients are estimated to develop bone metastases in the course of their disease
[<xref ref-type="bibr" rid="B3">3</xref>]. The clinical symptoms include pain at rest and under exercise, but also impaired activity of daily life (ADL), the risk of pathological fractures, and neurological deficits. Standard clinical care often includes patient immobilization either by means of an orthopedic thoracic corset or by confining the patient to bed in order to prevent pathological fractures. Regarding pain therapy and recalcification of former osteolytic lesions, palliative radiotherapy (RT) represents an effective treatment option
[<xref ref-type="bibr" rid="B4">4</xref>].</p><p>As the central axial organ of the human body, the vertebral column is involved in all physical movements and any spinal impairment with critically limited patient mobility. The paravertebral muscles greatly contribute to relief of pressure on the spine and, therefore, have a share in the realization of mobility. For this reason, exercise-related interventions have until now been excluded in patients with bone metastases, and the literature does not describe any targeted training-therapeutic measures involving isometric muscle exercise in these patients. There are, however, numerous findings that indicate the positive effect of targeted physical training measures in tumor patients regarding practicability, pain, and mobility
[<xref ref-type="bibr" rid="B5">5</xref>-<xref ref-type="bibr" rid="B10">10</xref>]. Correspondingly, the effect of resistance training as an adjunct to RT in patients with bone metastases is still unknown. In these patients with a generally advanced stage of the tumor, a painful vertebral column, and in a reduced general physical condition, this prospective trial presents a challenge in the investigation of the feasibility of a targeted, routine, and differentiated training program for strengthening the paravertebral muscles in patients with bone metastases of the vertebral column. An aspect of critical importance is first to distinguish between stable and unstable lesions, since an acute instability represents a contraindication for resistance training in patients with bone metastases. The aim of our trial was to analyze the feasibility of a combination therapy, in patients with spinal metastases in order to promote early mobility.</p></sec><sec sec-type="methods"><title>Methods</title><sec><title>Subjects, recruitment strategy, and eligibility for enrolment</title><p>From September 2011 to March 2013, 80 patients with a histologically confirmed tumor diagnosis and also solitary or multiple bone metastases of the thoracic or lumbar segments of the vertebral column or of the sacral region were screened in our department. Initially all patients were diagnosed with painful bone metastases requiring RT. Inclusion criteria were an age of 18 to 80&#x000a0;years, a Karnofsky performance score
[<xref ref-type="bibr" rid="B11">11</xref>]&#x02009;&#x02265;&#x02009;70, written declaration of informed consent, and already initiated bisphosphonate therapy. Furthermore, only patients with stable vertebral-body lesions were included. This was diagnosed independently by a specialist for radiology as well as by a specialist for orthopedic surgery. Only a metastasis classified by both specialists as &#x0201c;stable&#x0201d; was suggested eligible for inclusion. Patients with significant neurological or psychiatric disorders &#x02013; including dementia and epilepsy, contractual incapacity, and diagnosed vertebral-body instability or involvement of the cervical spine were excluded. Fifteen patients were excluded due to unstable metastases, and five patients declined to participate in the study. Sixty patients fulfilled the inclusion and exclusion criteria and were enrolled into the trial (Figure&#x000a0;
<xref ref-type="fig" rid="F1">1</xref>). The study was approved by the Heidelberg Ethics Committee (Nr. S-316/2011).</p><fig id="F1" position="float"><label>Figure 1</label><caption><p>Flow of participants through the trial.</p></caption><graphic xlink:href="1471-2407-14-67-1"/></fig></sec><sec><title>Design, randomized allocation, and procedures</title><p>This was a randomized, monocentre, controlled, explorative intervention study with the intention to determine the feasibility of a resistance training program for strengthening the paravertebral muscles in patients with spinal bone metastases under RT. The intervention was conducted initially under guidance and was subsequently continued by the individuals themselves. The control group underwent physical therapy in the form of respiration exercises and &#x0201c;hot roll&#x0201d; treatments. The patients were subjected to a staging of their vertebral column within the context of the computer tomography scans (CT) designed to plan the RT schedule prior to enrolment into the trial. In this examination the osteolytic metastases in the thoracic and lumbar spine were classified according to Taneichi
[<xref ref-type="bibr" rid="B12">12</xref>] and correspondingly classified as &#x0201c;stable&#x0201d; or &#x0201c;unstable&#x0201d;. The subtypes A-C were defined as &#x0201c;stable&#x0201d; in thoracic and lumbar spine (Figure&#x000a0;
<xref ref-type="fig" rid="F2">2</xref>). Osteoblastic and mixed metastases were assessed separately, since the Taneichi score can only be used for the assessment of osteolytic metastases. After completion of the measurement of the baseline findings, patients with stable bone metastases were allocated to one of the two treatment groups by randomization. A block randomization approach with block size 6 was used to ensure that the two intervention groups were balanced equally. A random list was used SAS 9.1. After the baseline measurements, the patients were assigned to the respective treatment arms on a 1:1 basis according to the randomization list. The randomization procedure was carried out by a central office. The data of the patient records were collected by the authors. The evaluation included all recorded data up to the time of the three-month follow-up interval. The data of the patient characteristics are presented in summary Table&#x000a0;
<xref ref-type="table" rid="T1">1</xref>.</p><fig id="F2" position="float"><label>Figure 2</label><caption><p><bold>Taneichi score </bold>[<xref ref-type="bibr" rid="B20">20</xref>]<bold>.</bold></p></caption><graphic xlink:href="1471-2407-14-67-2"/></fig><table-wrap position="float" id="T1"><label>Table 1</label><caption><p>Patient characteristics at baseline</p></caption><table frame="hsides" rules="groups" border="1"><colgroup><col align="left"/><col align="left"/><col align="left"/><col align="left"/><col align="left"/><col align="center"/></colgroup><thead valign="top"><tr><th rowspan="2" align="left">&#x000a0;</th><th colspan="2" align="center" valign="bottom"><bold>Intervention group (n&#x02009;=&#x02009;30)</bold><hr/></th><th colspan="2" align="center" valign="bottom"><bold>Control group (n&#x02009;=&#x02009;30)</bold><hr/></th><th align="center" valign="bottom"><bold>p-value</bold><hr/></th></tr><tr><th align="left"><bold>n</bold></th><th align="left"><bold>%</bold></th><th align="left"><bold>n</bold></th><th align="left"><bold>%</bold></th><th align="center">&#x000a0;</th></tr></thead><tbody valign="top"><tr><td colspan="6" align="left" valign="bottom">Age (years)<hr/></td></tr><tr><td align="left" valign="bottom">&#x02003;Mean (SD)<hr/></td><td align="left" valign="bottom">61.3 (10.1)<hr/></td><td align="left" valign="bottom">&#x000a0;<hr/></td><td align="left" valign="bottom">64.1 (10.9)<hr/></td><td align="left" valign="bottom">&#x000a0;<hr/></td><td align="center" valign="bottom">0.304<hr/></td></tr><tr><td colspan="6" align="left" valign="bottom">Gender<hr/></td></tr><tr><td align="left" valign="bottom">&#x02003;Male<hr/></td><td align="left" valign="bottom">14<hr/></td><td align="left" valign="bottom">46.7<hr/></td><td align="left" valign="bottom">19<hr/></td><td align="left" valign="bottom">63.3<hr/></td><td align="center" valign="bottom">0.195<hr/></td></tr><tr><td align="left" valign="bottom">&#x02003;Female<hr/></td><td align="left" valign="bottom">16<hr/></td><td align="left" valign="bottom">53.3<hr/></td><td align="left" valign="bottom">11<hr/></td><td align="left" valign="bottom">36.7<hr/></td><td align="center" valign="bottom">&#x000a0;<hr/></td></tr><tr><td align="left" valign="bottom">Weight (kg, SD)<hr/></td><td align="left" valign="bottom">74.3 (14.7)<hr/></td><td align="left" valign="bottom">&#x000a0;<hr/></td><td align="left" valign="bottom">72.7 (12.1)<hr/></td><td align="left" valign="bottom">&#x000a0;<hr/></td><td align="center" valign="bottom">0.553<hr/></td></tr><tr><td align="left" valign="bottom">Height (cm, SD)<hr/></td><td align="left" valign="bottom">171.2 (8.3)<hr/></td><td align="left" valign="bottom">&#x000a0;<hr/></td><td align="left" valign="bottom">172.3 (7.5)<hr/></td><td align="left" valign="bottom">&#x000a0;<hr/></td><td align="center" valign="bottom">0.906<hr/></td></tr><tr><td colspan="6" align="left" valign="bottom">Body mass index<hr/></td></tr><tr><td align="left" valign="bottom">&#x02003;Mean (SD)<hr/></td><td align="left" valign="bottom">25.3 (4.5)<hr/></td><td align="left" valign="bottom">&#x000a0;<hr/></td><td align="left" valign="bottom">24.4 (3.6)<hr/></td><td align="left" valign="bottom">&#x000a0;<hr/></td><td align="center" valign="bottom">0.559<hr/></td></tr><tr><td align="left" valign="bottom">Karnofsky-index (median, range)<hr/></td><td align="left" valign="bottom">80 (70&#x02013;100)<hr/></td><td align="left" valign="bottom">&#x000a0;<hr/></td><td align="left" valign="bottom">80 (70&#x02013;100)<hr/></td><td align="left" valign="bottom">&#x000a0;<hr/></td><td align="center" valign="bottom">1.000<hr/></td></tr><tr><td colspan="6" align="left" valign="bottom">Primary site<hr/></td></tr><tr><td align="left" valign="bottom">&#x02003;Lung cancer<hr/></td><td align="left" valign="bottom">12<hr/></td><td align="left" valign="bottom">9.2<hr/></td><td align="left" valign="bottom">8<hr/></td><td align="left" valign="bottom">26.6<hr/></td><td align="center" valign="bottom">0.320<hr/></td></tr><tr><td align="left" valign="bottom">&#x02003;Breast cancer<hr/></td><td align="left" valign="bottom">5<hr/></td><td align="left" valign="bottom">16.7<hr/></td><td align="left" valign="bottom">6<hr/></td><td align="left" valign="bottom">20.1<hr/></td><td align="center" valign="bottom">0.542<hr/></td></tr><tr><td align="left" valign="bottom">&#x02003;Prostate cancer<hr/></td><td align="left" valign="bottom">5<hr/></td><td align="left" valign="bottom">16.7<hr/></td><td align="left" valign="bottom">9<hr/></td><td align="left" valign="bottom">30.1<hr/></td><td align="center" valign="bottom">0.156<hr/></td></tr><tr><td align="left" valign="bottom">&#x02003;Melanoma<hr/></td><td align="left" valign="bottom">1<hr/></td><td align="left" valign="bottom">3.3<hr/></td><td align="left" valign="bottom">1<hr/></td><td align="left" valign="bottom">3.3<hr/></td><td align="center" valign="bottom">1.000<hr/></td></tr><tr><td align="left" valign="bottom">&#x02003;Renal cancer<hr/></td><td align="left" valign="bottom">1<hr/></td><td align="left" valign="bottom">3.3<hr/></td><td align="left" valign="bottom">2<hr/></td><td align="left" valign="bottom">6.7<hr/></td><td align="center" valign="bottom">0.875<hr/></td></tr><tr><td align="left" valign="bottom">&#x02003;Other<hr/></td><td align="left" valign="bottom">6<hr/></td><td align="left" valign="bottom">20.1<hr/></td><td align="left" valign="bottom">4<hr/></td><td align="left" valign="bottom">13.4<hr/></td><td align="center" valign="bottom">0.325<hr/></td></tr><tr><td align="left" valign="bottom">Localization metastases<hr/></td><td align="left" valign="bottom">&#x000a0;<hr/></td><td align="left" valign="bottom">&#x000a0;<hr/></td><td align="left" valign="bottom">&#x000a0;<hr/></td><td align="left" valign="bottom">&#x000a0;<hr/></td><td align="center" valign="bottom">0.717<hr/></td></tr><tr><td align="left" valign="bottom">&#x02003;Thoracic<hr/></td><td align="left" valign="bottom">17<hr/></td><td align="left" valign="bottom">56.7<hr/></td><td align="left" valign="bottom">14<hr/></td><td align="left" valign="bottom">46.7<hr/></td><td align="center" valign="bottom">&#x000a0;<hr/></td></tr><tr><td align="left" valign="bottom">&#x02003;Lumbar<hr/></td><td align="left" valign="bottom">9<hr/></td><td align="left" valign="bottom">30.0<hr/></td><td align="left" valign="bottom">13<hr/></td><td align="left" valign="bottom">43.3<hr/></td><td align="center" valign="bottom">&#x000a0;<hr/></td></tr><tr><td align="left" valign="bottom">&#x02003;Thoracic and lumbar<hr/></td><td align="left" valign="bottom">2<hr/></td><td align="left" valign="bottom">6.7<hr/></td><td align="left" valign="bottom">2<hr/></td><td align="left" valign="bottom">6.7<hr/></td><td align="center" valign="bottom">&#x000a0;<hr/></td></tr><tr><td align="left" valign="bottom">&#x02003;Sacrum<hr/></td><td align="left" valign="bottom">2<hr/></td><td align="left" valign="bottom">6.7<hr/></td><td align="left" valign="bottom">1<hr/></td><td align="left" valign="bottom">3.3<hr/></td><td align="center" valign="bottom">&#x000a0;<hr/></td></tr><tr><td align="left" valign="bottom">Number metastases<hr/></td><td align="left" valign="bottom">&#x000a0;<hr/></td><td align="left" valign="bottom">&#x000a0;<hr/></td><td align="left" valign="bottom">&#x000a0;<hr/></td><td align="left" valign="bottom">&#x000a0;<hr/></td><td align="center" valign="bottom">0.257<hr/></td></tr><tr><td align="left" valign="bottom">&#x02003;Mean (range)<hr/></td><td align="left" valign="bottom">1.4 (2&#x02013;4)<hr/></td><td align="left" valign="bottom">&#x000a0;<hr/></td><td align="left" valign="bottom">1.7 (1&#x02013;5)<hr/></td><td align="left" valign="bottom">&#x000a0;<hr/></td><td align="center" valign="bottom">&#x000a0;<hr/></td></tr><tr><td align="left" valign="bottom">&#x02003;Solitary<hr/></td><td align="left" valign="bottom">22<hr/></td><td align="left" valign="bottom">73.3<hr/></td><td align="left" valign="bottom">18<hr/></td><td align="left" valign="bottom">60.0<hr/></td><td align="center" valign="bottom">&#x000a0;<hr/></td></tr><tr><td align="left" valign="bottom">&#x02003;Multiple<hr/></td><td align="left" valign="bottom">8<hr/></td><td align="left" valign="bottom">26.7<hr/></td><td align="left" valign="bottom">12<hr/></td><td align="left" valign="bottom">40.0<hr/></td><td align="center" valign="bottom">&#x000a0;<hr/></td></tr><tr><td align="left" valign="bottom">Type of metastases<hr/></td><td align="left" valign="bottom">&#x000a0;<hr/></td><td align="left" valign="bottom">&#x000a0;<hr/></td><td align="left" valign="bottom">&#x000a0;<hr/></td><td align="left" valign="bottom">&#x000a0;<hr/></td><td align="center" valign="bottom">0.961<hr/></td></tr><tr><td align="left" valign="bottom">&#x02003;Mixed<hr/></td><td align="left" valign="bottom">2<hr/></td><td align="left" valign="bottom">6.7<hr/></td><td align="left" valign="bottom">2<hr/></td><td align="left" valign="bottom">6.7<hr/></td><td align="center" valign="bottom">1.000<hr/></td></tr><tr><td align="left" valign="bottom">&#x02003;Osteoblast<hr/></td><td align="left" valign="bottom">9<hr/></td><td align="left" valign="bottom">30.0<hr/></td><td align="left" valign="bottom">10<hr/></td><td align="left" valign="bottom">33.3<hr/></td><td align="center" valign="bottom">0.956<hr/></td></tr><tr><td align="left" valign="bottom">&#x02003;Osteolytic<hr/></td><td align="left" valign="bottom">19<hr/></td><td align="left" valign="bottom">63.3<hr/></td><td align="left" valign="bottom">18<hr/></td><td align="left" valign="bottom">60.0<hr/></td><td align="center" valign="bottom">.0932<hr/></td></tr><tr><td align="left" valign="bottom">Distant metastases at baseline<hr/></td><td align="left" valign="bottom">&#x000a0;<hr/></td><td align="left" valign="bottom">&#x000a0;<hr/></td><td align="left" valign="bottom">&#x000a0;<hr/></td><td align="left" valign="bottom">&#x000a0;<hr/></td><td align="center" valign="bottom">&#x000a0;<hr/></td></tr><tr><td align="left" valign="bottom">&#x02003;Visceral<hr/></td><td align="left" valign="bottom">12<hr/></td><td align="left" valign="bottom">40.0<hr/></td><td align="left" valign="bottom">5<hr/></td><td align="left" valign="bottom">16.7<hr/></td><td align="center" valign="bottom">0.045<hr/></td></tr><tr><td align="left" valign="bottom">&#x02003;Brain<hr/></td><td align="left" valign="bottom">3<hr/></td><td align="left" valign="bottom">10.0<hr/></td><td align="left" valign="bottom">3<hr/></td><td align="left" valign="bottom">10.0<hr/></td><td align="center" valign="bottom">1.000<hr/></td></tr><tr><td align="left" valign="bottom">&#x02003;Lung<hr/></td><td align="left" valign="bottom">7<hr/></td><td align="left" valign="bottom">23.3<hr/></td><td align="left" valign="bottom">4<hr/></td><td align="left" valign="bottom">13.3<hr/></td><td align="center" valign="bottom">0.320<hr/></td></tr><tr><td align="left" valign="bottom">&#x02003;Tissue<hr/></td><td align="left" valign="bottom">8<hr/></td><td align="left" valign="bottom">26.7<hr/></td><td align="left" valign="bottom">6<hr/></td><td align="left" valign="bottom">20.0<hr/></td><td align="center" valign="bottom">0.542<hr/></td></tr><tr><td align="left" valign="bottom">Hormonotherapy<hr/></td><td align="left" valign="bottom">10<hr/></td><td align="left" valign="bottom">33.3<hr/></td><td align="left" valign="bottom">16<hr/></td><td align="left" valign="bottom">53.3<hr/></td><td align="center" valign="bottom">0.118<hr/></td></tr><tr><td align="left" valign="bottom">Immunotherapy<hr/></td><td align="left" valign="bottom">7<hr/></td><td align="left" valign="bottom">23.3<hr/></td><td align="left" valign="bottom">5<hr/></td><td align="left" valign="bottom">16.7<hr/></td><td align="center" valign="bottom">0.519<hr/></td></tr><tr><td align="left" valign="bottom">Chemotherapy<hr/></td><td align="left" valign="bottom">25<hr/></td><td align="left" valign="bottom">83.3<hr/></td><td align="left" valign="bottom">20<hr/></td><td align="left" valign="bottom">66.7<hr/></td><td align="center" valign="bottom">0.136<hr/></td></tr><tr><td align="left" valign="bottom">Pathological fracture at baseline<hr/></td><td align="left" valign="bottom">6<hr/></td><td align="left" valign="bottom">20.0<hr/></td><td align="left" valign="bottom">9<hr/></td><td align="left" valign="bottom">30.0<hr/></td><td align="center" valign="bottom">0.379<hr/></td></tr><tr><td align="left" valign="bottom">Neurological deficit<hr/></td><td align="left" valign="bottom">0<hr/></td><td align="left" valign="bottom">0.0<hr/></td><td align="left" valign="bottom">2<hr/></td><td align="left" valign="bottom">6.7<hr/></td><td align="center" valign="bottom">0.150<hr/></td></tr><tr><td align="left" valign="bottom">Orthopedic corset at baseline<hr/></td><td align="left" valign="bottom">7<hr/></td><td align="left" valign="bottom">23.3<hr/></td><td align="left" valign="bottom">5<hr/></td><td align="left" valign="bottom">16.7<hr/></td><td align="center" valign="bottom">0.519<hr/></td></tr><tr><td align="left" valign="bottom">Radiotherapy dose completed (Gy)<hr/></td><td align="left" valign="bottom">&#x000a0;<hr/></td><td align="left" valign="bottom">&#x000a0;<hr/></td><td align="left" valign="bottom">&#x000a0;<hr/></td><td align="left" valign="bottom">&#x000a0;<hr/></td><td align="center" valign="bottom">0.136<hr/></td></tr><tr><td align="left" valign="bottom">&#x02003;Single dose (median, range)<hr/></td><td align="left" valign="bottom">3 (2&#x02013;4)<hr/></td><td align="left" valign="bottom">&#x000a0;<hr/></td><td align="left" valign="bottom">3 (2&#x02013;4)<hr/></td><td align="left" valign="bottom">&#x000a0;<hr/></td><td align="center" valign="bottom">1.000<hr/></td></tr><tr><td align="left">&#x02003;Cumulative dose (median, range)</td><td align="left">30 (30&#x02013;40)</td><td align="left">&#x000a0;</td><td align="left">30 (30&#x02013;40)</td><td align="left">&#x000a0;</td><td align="center">1.000</td></tr></tbody></table><table-wrap-foot><p><italic>Abbreviations</italic>: <italic>SD</italic> Standard deviation.</p></table-wrap-foot></table-wrap></sec><sec><title>Study interventions</title><p>Arm A (intervention group, differentiated resistance training) and in Arm B (control group, physical &#x0201c;respiratory&#x0201d; measure) each consisted of 30 patients. The interventions started on the same day with RT and were performed on each of the treatment days (Monday until Friday) over a two-week period, independent of the number of RT fractions. The sports intervention lasted approximately 30&#x000a0;min, the &#x0201c;respiratory&#x0201d; measure approximately 15&#x000a0;min
[<xref ref-type="bibr" rid="B13">13</xref>]. The patients exhibit differences in terms of age, physical constitution, gender, stage of tumor, general state of health, bone density, and pain symptoms, which is why the muscle-exercise concept was kept as simple as possible. Since the site of the bone metastases differed from patient to patient, three different exercises were enacted to ensure an even isometric training of the muscles along the entire vertebral column. The participants of the control group were given physical therapy in the form of respiration exercises and &#x0201c;hot roll&#x0201d; treatments also for a period of two weeks. A detailed report of the sports intervention and its application has already been published
[<xref ref-type="bibr" rid="B14">14</xref>].</p><p>After completion of RT schedule or, respectively, after two weeks, patients in the training group were guided to continue exercises, which were demonstrated to them by their therapist in the one-on-one situation, on their own at home for a further twelve weeks. The training exercises were documented. The patients in the control group did not carry out any further measures at home after the two-week therapy period. The target parameters were measured at the start of RT (t<sub>0</sub>), at the end (t<sub>1</sub>), and after twelve weeks (t<sub>2</sub>). The target parameters comprise the documentation of the training program, the pain score according to the visual analog scale (VAS), the completion of the activity questionnaire, and the recording of patient-specific data. Since it was not possible to quantitatively measure the power of the paravertebral muscles as a baseline value and to monitor the success of the training, the so-called &#x0201c;chair stand&#x0201d; test
[<xref ref-type="bibr" rid="B15">15</xref>] was carried out at all measurement intervals. In this test the subjects were asked to stand up from the sitting position as many times as possible within a period of 30&#x000a0;seconds, with the number of times being recorded as the score.</p></sec><sec><title>Assessment of the primary and secondary endpoints</title><p>The aim of the trial was to evaluate the feasibility of the defined training program. The feasibility as the primary endpoint was defined as the completion of the training program up to three months after the end of RT (t<sub>2</sub>). In addition, the evaluation of the mobility aspect included the performance of the chair-stand test at the individual investigation intervals. The item taken as the secondary endpoint was the activity of the patients as documented on an activity questionnaire specially designed for this trial and completed on the individual days of examination (Table&#x000a0;
<xref ref-type="table" rid="T2">2</xref>). We created questions independently which were relevant for these palliative patients. Furthermore, the local control was assessed by means of CT images taken prior to and three months after RT. The pain response was documented on the VAS (range 0&#x02013;10). Complete response (CR) was defined as VAS&#x02009;=&#x02009;0 after three months, partial response (PR) as an improvement by at least two score points after three months, according to the international consensus response categories by Chow et al.
[<xref ref-type="bibr" rid="B16">16</xref>]. Overall survival (OS) was defined as time from initial diagnosis until death, bone survival as time from initial diagnosis of spinal bone metastasis until death.</p><table-wrap position="float" id="T2"><label>Table 2</label><caption><p>Questions of the activity questionnaire</p></caption><table frame="hsides" rules="groups" border="1"><colgroup><col align="left"/><col align="left"/></colgroup><thead valign="top"><tr><th align="left">&#x000a0;</th><th align="left">&#x000a0;</th></tr></thead><tbody valign="top"><tr><td align="left" valign="bottom">1.<hr/></td><td align="left" valign="bottom">I don&#x02019;t have any trouble putting on my socks/shoes on my own. (absolutely true&#x02009;=&#x02009;1 to absolutely false&#x02009;=&#x02009;6)<hr/></td></tr><tr><td align="left" valign="bottom">2.<hr/></td><td align="left" valign="bottom">I don&#x02019;t have any trouble putting on a t-shirt on my own. (absolutely true&#x02009;=&#x02009;1 to absolutely false&#x02009;=&#x02009;6)<hr/></td></tr><tr><td align="left" valign="bottom">3.<hr/></td><td align="left" valign="bottom">I have trouble getting up from a low chair. (absolutely true&#x02009;=&#x02009;1 to absolutely false&#x02009;=&#x02009;6)<hr/></td></tr><tr><td align="left" valign="bottom">4.<hr/></td><td align="left" valign="bottom">I don&#x02019;t have any trouble getting into a car. (absolutely true&#x02009;=&#x02009;1 to absolutely false&#x02009;=&#x02009;6)<hr/></td></tr><tr><td align="left" valign="bottom">5.<hr/></td><td align="left" valign="bottom">The longest distance I can currently walk is approx. &#x0003c;100&#x000a0;m; 100&#x02013;500&#x000a0;m; 500-1000&#x000a0;m; 1&#x02013;2&#x000a0;km; 2&#x02013;5&#x000a0;km; &#x0003e; 5&#x000a0;km<hr/></td></tr><tr><td align="left" valign="bottom">6.<hr/></td><td align="left" valign="bottom">After covering this distance I&#x02019;m thoroughly exhausted. (absolutely true&#x02009;=&#x02009;1 to absolutely false&#x02009;=&#x02009;6)<hr/></td></tr><tr><td align="left" valign="bottom">7.<hr/></td><td align="left" valign="bottom">I&#x02019;m still capable of riding a bicycle yes&#x02009;=&#x02009;1; no&#x02009;=&#x02009;0<hr/></td></tr><tr><td align="left" valign="bottom">8.<hr/></td><td align="left" valign="bottom">The longest riding distance I&#x02019;m still capable of is approx. &#x0003c;2&#x000a0;km; 2&#x02013;5&#x000a0;km; 5&#x02013;10&#x000a0;km; 10&#x02013;15&#x000a0;km; 15&#x02013;20&#x000a0;km; &#x0003e;20&#x000a0;km<hr/></td></tr><tr><td align="left" valign="bottom">9.<hr/></td><td align="left" valign="bottom">After riding this distance I&#x02019;m thoroughly exhausted. (absolutely true&#x02009;=&#x02009;1 to absolutely false&#x02009;=&#x02009;6)<hr/></td></tr><tr><td align="left" valign="bottom">10.<hr/></td><td align="left" valign="bottom">I can walk up stairs from one storey to the next with ease. (absolutely true&#x02009;=&#x02009;1 to absolutely false&#x02009;=&#x02009;6)<hr/></td></tr><tr><td align="left">11.</td><td align="left">I don&#x02019;t have any trouble carrying a shopping basket approx. 50&#x000a0;m. (absolutely true&#x02009;=&#x02009;1 to absolutely false&#x02009;=&#x02009;6)</td></tr></tbody></table></table-wrap></sec><sec><title>Compliance with the intervention</title><p>During the two-week period of RT, patients in the training group (Arm A) performed exercises under the guidance of a physiotherapist. The patients were then requested to carry out the defined training program in their home setting three times a week and to document the exercises themselves. We could improve the compliance with no implements for home training, and the exercises were practicable easily. This training schedule was verified at the t<sub>2</sub> follow-up interval.</p></sec><sec><title>Radiotherapy</title><p>Radiotherapy was performed in our department. After virtual simulation was performed to plan the radiation schedule, radiotherapy was carried out over a dorsal photon field of the 6MV energy range. Primary target volume (PTV) covered the specific vertebral body affected as well as the ones immediately above and below. In Arm A, 24 patients (80%) were treated with 10&#x02009;&#x000d7;&#x02009;3&#x000a0;Gy, three patients (10%) with 14&#x02009;&#x000d7;&#x02009;2.5&#x000a0;Gy, and three patients (10%) with 20&#x02009;&#x000d7;&#x02009;2&#x000a0;Gy. In Arm B, the RT protocols for 28 patients (93.4%) were 10&#x02009;&#x000d7;&#x02009;3&#x000a0;Gy, for one patient (3.3%) 14&#x02009;&#x000d7;&#x02009;2.5&#x000a0;Gy, and for one patient (3.3%) 20&#x02009;&#x000d7;&#x02009;2&#x000a0;Gy. The median single dose was 3&#x000a0;Gy (range 2&#x02013;3&#x000a0;Gy), the median total dose 30&#x000a0;Gy (range 20&#x02013;35&#x000a0;Gy). The single and total doses were decided separately for each patient, depending on the histology, the patient&#x02019;s general state of health, and on the current staging and the corresponding prognosis.</p></sec><sec><title>Sample calculation and statistical analysis</title><p>The total number of patients undergoing radiotherapy in the radiation oncology department of the Heidelberg University Clinic for metastatic processes in the vertebral column in the recruitment period is approximately 120, about 90 of whom shall fulfill the inclusion criteria. On account of the explorative character of this study it was not possible to estimate the total number of cases; with a scheduled number of 30 patients per group, it will, however, be possible to detect a standardized mean-value effect of 0.8 with a power of 80% and an &#x003b1; significance level of 5%. All variables were analyzed descriptively by tabulation of the measures of the empirical distributions. According to the scale level of the variables, means, standard deviations, medians as well as minimum and maximum or absolute and relative frequencies, respectively, will be reported. The results are reported as p-values. For all analysis, a p-value of 0.05 or less was considered significant. All statistical analyses were done using SAS software Version 9.1 (SAS Institute, Cary, NC, USA).</p></sec></sec><sec sec-type="results"><title>Results</title><p>Groups were balanced at baseline. The median follow-up was 3.3&#x000a0;months for both groups (range 2.8-4.0&#x000a0;months). Patients in the intervention group (Arm A) completed the isometric resistance training of the autochthonous muscles in 83.3% (n&#x02009;=&#x02009;25) of all cases. Five patients (16.7%) died within the first twelve weeks following RT due to tumor progression. In Arm B, 7 patients (23.3%) died within 3&#x000a0;months. In the intervention group, fatigue and psychological stress decreased during the training program (p&#x02009;&#x0003c;&#x02009;.001), and there was a significant difference between baseline and after 3&#x000a0;month in both parameters (p&#x02009;&#x0003c;&#x02009;.001) (Table&#x000a0;
<xref ref-type="table" rid="T3">3</xref>). Pathological fractures or progression of a neurological deficit did not occur in both groups. Patients in Arm A improved significantly in the chair-stand test (p&#x02009;&#x0003c;&#x02009;.0001) over the course, and between groups in favor to intervention group (p&#x02009;&#x0003c;&#x02009;.001). No significant difference could be measured in the control group (p&#x02009;=&#x02009;.525) (Table&#x000a0;
<xref ref-type="table" rid="T4">4</xref>). This result is also reflected in the evaluation of the activity questionnaire (Tables&#x000a0;
<xref ref-type="table" rid="T2">2</xref> and
<xref ref-type="table" rid="T5">5</xref>). After three months, none of the patients (n&#x02009;=&#x02009;0; 0%) in the intervention group required an orthopedic thoracic corset any longer, while the difference in Arm B was unchanged (n&#x02009;=&#x02009;4; 17.4%).</p><table-wrap position="float" id="T3"><label>Table 3</label><caption><p>Intervention group</p></caption><table frame="hsides" rules="groups" border="1"><colgroup><col align="left"/><col align="center"/><col align="center"/><col align="center"/><col align="center"/><col align="center"/></colgroup><thead valign="top"><tr><th align="left">&#x000a0;</th><th align="center"><bold>Mean</bold></th><th align="center"><bold>SD</bold></th><th align="center"><bold>Min</bold></th><th align="center"><bold>Median</bold></th><th align="center"><bold>Max</bold></th></tr></thead><tbody valign="top"><tr><td align="left" valign="bottom"><bold>Previous training</bold><hr/></td><td align="center" valign="bottom">&#x000a0;<hr/></td><td align="center" valign="bottom">&#x000a0;<hr/></td><td align="center" valign="bottom">&#x000a0;<hr/></td><td align="center" valign="bottom">&#x000a0;<hr/></td><td align="center" valign="bottom">&#x000a0;<hr/></td></tr><tr><td align="left" valign="bottom">Felling sluggish (pts. 1&#x02013;6)<hr/></td><td align="center" valign="bottom">2.8<hr/></td><td align="center" valign="bottom">0.9<hr/></td><td align="center" valign="bottom">1.2<hr/></td><td align="center" valign="bottom">2.9<hr/></td><td align="center" valign="bottom">5.4<hr/></td></tr><tr><td align="left" valign="bottom">Psychological stress (pts. 1&#x02013;6)<hr/></td><td align="center" valign="bottom">2.6<hr/></td><td align="center" valign="bottom">0.9<hr/></td><td align="center" valign="bottom">1.2<hr/></td><td align="center" valign="bottom">2.8<hr/></td><td align="center" valign="bottom">5.1<hr/></td></tr><tr><td align="left" valign="bottom"><bold>After training</bold><hr/></td><td align="center" valign="bottom">&#x000a0;<hr/></td><td align="center" valign="bottom">&#x000a0;<hr/></td><td align="center" valign="bottom">&#x000a0;<hr/></td><td align="center" valign="bottom">&#x000a0;<hr/></td><td align="center" valign="bottom">&#x000a0;<hr/></td></tr><tr><td align="left" valign="bottom">Felling sluggish (pts. 1&#x02013;6)<hr/></td><td align="center" valign="bottom">2.2<hr/></td><td align="center" valign="bottom">0.9<hr/></td><td align="center" valign="bottom">1.1<hr/></td><td align="center" valign="bottom">2.0<hr/></td><td align="center" valign="bottom">5.0<hr/></td></tr><tr><td align="left" valign="bottom">Psychological stress (pts. 1&#x02013;6)<hr/></td><td align="center" valign="bottom">2.1<hr/></td><td align="center" valign="bottom">0.8<hr/></td><td align="center" valign="bottom">1.1<hr/></td><td align="center" valign="bottom">1.9<hr/></td><td align="center" valign="bottom">4.6<hr/></td></tr><tr><td align="left" valign="bottom">Teatment effect (previous vs. after)<hr/></td><td colspan="4" align="center" valign="bottom">p&#x02009;&#x0003c;&#x02009;.001 in both parameters<hr/></td><td align="center" valign="bottom">&#x000a0;<hr/></td></tr><tr><td align="left" valign="bottom">Difference T0-T2<hr/></td><td colspan="4" align="center" valign="bottom">p&#x02009;&#x0003c;&#x02009;.001 in both parameters<hr/></td><td align="center" valign="bottom">&#x000a0;<hr/></td></tr><tr><td align="left" valign="bottom">Pain during intervention (n, %)<hr/></td><td align="center" valign="bottom">&#x000a0;<hr/></td><td align="center" valign="bottom">5 (16.7)<hr/></td><td align="center" valign="bottom">&#x000a0;<hr/></td><td align="center" valign="bottom">&#x000a0;<hr/></td><td align="center" valign="bottom">&#x000a0;<hr/></td></tr><tr><td align="left">Pain medication needed (n, %)</td><td align="center">&#x000a0;</td><td align="center">4 (13.3)</td><td align="center">&#x000a0;</td><td align="center">&#x000a0;</td><td align="center">&#x000a0;</td></tr></tbody></table><table-wrap-foot><p>This table shows the results of a questionnaire previous and after intervention respective feeling sluggish and psychological stress (pt 1&#x02009;=&#x02009;least to pt 6&#x02009;=&#x02009;most). Treatment effect (previous vs. after training) and difference in both parameters were significant (p&#x02009;&#x0003c;&#x02009;.001). Pain during intervention was documented according VAS-scale (0&#x02013;10). Concomitant pain medication during intervention was evaluated (number of patients, %).</p></table-wrap-foot></table-wrap><table-wrap position="float" id="T4"><label>Table 4</label><caption><p>Results of &#x0201c;chair stand test&#x0201d; and pain response</p></caption><table frame="hsides" rules="groups" border="1"><colgroup><col align="left"/><col align="center"/><col align="center"/><col align="center"/><col align="center"/><col align="center"/><col align="center"/><col align="center"/><col align="center"/><col align="center"/><col align="center"/><col align="center"/><col align="center"/></colgroup><thead valign="top"><tr><th align="left" valign="bottom"><bold>Chair stand test</bold><hr/></th><th align="center" valign="bottom">&#x000a0;<hr/></th><th colspan="5" align="center" valign="bottom"><bold>Intervention group (n&#x02009;=&#x02009;30)</bold><hr/></th><th align="center" valign="bottom">&#x000a0;<hr/></th><th colspan="4" align="center" valign="bottom"><bold>Control group (n&#x02009;=&#x02009;30)</bold><hr/></th><th align="center" valign="bottom">&#x000a0;<hr/></th></tr><tr><th align="left">&#x000a0;</th><th align="center"><bold>n</bold></th><th align="center"><bold>Mean</bold></th><th align="center"><bold>SD</bold></th><th align="center"><bold>Min</bold></th><th align="center"><bold>Median</bold></th><th align="center"><bold>Max</bold></th><th align="center"><bold>n</bold></th><th align="center"><bold>Mean</bold></th><th align="center"><bold>SD</bold></th><th align="center"><bold>Min</bold></th><th align="center"><bold>Median</bold></th><th align="center"><bold>Max</bold></th></tr></thead><tbody valign="top"><tr><td align="left" valign="bottom">Baseline (t0)<hr/></td><td align="center" valign="bottom">30<hr/></td><td align="center" valign="bottom">5.1<hr/></td><td align="center" valign="bottom">1.4<hr/></td><td align="center" valign="bottom">2.0<hr/></td><td align="center" valign="bottom">5.0<hr/></td><td align="center" valign="bottom">7.0<hr/></td><td align="center" valign="bottom">30<hr/></td><td align="center" valign="bottom">4.6<hr/></td><td align="center" valign="bottom">2.0<hr/></td><td align="center" valign="bottom">0.0<hr/></td><td align="center" valign="bottom">4.0<hr/></td><td align="center" valign="bottom">9.0<hr/></td></tr><tr><td align="left" valign="bottom">End of RT (t1)<hr/></td><td align="center" valign="bottom">30<hr/></td><td align="center" valign="bottom">6.7<hr/></td><td align="center" valign="bottom">1.9<hr/></td><td align="center" valign="bottom">4.0<hr/></td><td align="center" valign="bottom">6.5<hr/></td><td align="center" valign="bottom">12.0<hr/></td><td align="center" valign="bottom">30<hr/></td><td align="center" valign="bottom">4.9<hr/></td><td align="center" valign="bottom">2.2<hr/></td><td align="center" valign="bottom">0.0<hr/></td><td align="center" valign="bottom">5.0<hr/></td><td align="center" valign="bottom">10.0<hr/></td></tr><tr><td align="left" valign="bottom">After 3&#x000a0;month (t2)<hr/></td><td align="center" valign="bottom">25<hr/></td><td align="center" valign="bottom">9.0<hr/></td><td align="center" valign="bottom">2.6<hr/></td><td align="center" valign="bottom">5.0<hr/></td><td align="center" valign="bottom">10.0<hr/></td><td align="center" valign="bottom">13.0<hr/></td><td align="center" valign="bottom">23<hr/></td><td align="center" valign="bottom">5.0<hr/></td><td align="center" valign="bottom">2.7<hr/></td><td align="center" valign="bottom">0.0<hr/></td><td align="center" valign="bottom">5.0<hr/></td><td align="center" valign="bottom">10.0<hr/></td></tr><tr><td align="left" valign="bottom">Treatment effect within groups (t2)<hr/></td><td align="center" valign="bottom">&#x000a0;<hr/></td><td align="center" valign="bottom">p&#x02009;&#x0003c;&#x02009;.001<hr/></td><td align="center" valign="bottom">&#x000a0;<hr/></td><td align="center" valign="bottom">&#x000a0;<hr/></td><td align="center" valign="bottom">&#x000a0;<hr/></td><td align="center" valign="bottom">&#x000a0;<hr/></td><td align="center" valign="bottom">&#x000a0;<hr/></td><td align="center" valign="bottom">p&#x02009;=&#x02009;0.525<hr/></td><td align="center" valign="bottom">&#x000a0;<hr/></td><td align="center" valign="bottom">&#x000a0;<hr/></td><td align="center" valign="bottom">&#x000a0;<hr/></td><td align="center" valign="bottom">&#x000a0;<hr/></td></tr><tr><td align="left" valign="bottom">Treatment effect between groups (t2)<hr/></td><td align="center" valign="bottom">&#x000a0;<hr/></td><td colspan="2" align="center" valign="bottom">p&#x02009;&#x0003c;&#x02009;.001<hr/></td><td align="center" valign="bottom">&#x000a0;<hr/></td><td align="center" valign="bottom">&#x000a0;<hr/></td><td align="center" valign="bottom">&#x000a0;<hr/></td><td align="center" valign="bottom">&#x000a0;<hr/></td><td align="center" valign="bottom">&#x000a0;<hr/></td><td align="center" valign="bottom">&#x000a0;<hr/></td><td align="center" valign="bottom">&#x000a0;<hr/></td><td align="center" valign="bottom">&#x000a0;<hr/></td><td align="center" valign="bottom">&#x000a0;<hr/></td></tr><tr><td align="left" valign="bottom"><bold>pain response (VAS 0&#x02013;10)</bold><hr/></td><td align="center" valign="bottom">&#x000a0;<hr/></td><td align="center" valign="bottom">&#x000a0;<hr/></td><td align="center" valign="bottom">&#x000a0;<hr/></td><td align="center" valign="bottom">&#x000a0;<hr/></td><td align="center" valign="bottom">&#x000a0;<hr/></td><td align="center" valign="bottom">&#x000a0;<hr/></td><td align="center" valign="bottom">&#x000a0;<hr/></td><td align="center" valign="bottom">&#x000a0;<hr/></td><td align="center" valign="bottom">&#x000a0;<hr/></td><td align="center" valign="bottom">&#x000a0;<hr/></td><td align="center" valign="bottom">&#x000a0;<hr/></td><td align="center" valign="bottom">&#x000a0;<hr/></td></tr><tr><td align="left" valign="bottom">Pain score at baseline (VAS)<hr/></td><td align="center" valign="bottom">30<hr/></td><td align="center" valign="bottom">4.8<hr/></td><td align="center" valign="bottom">2.1<hr/></td><td align="center" valign="bottom">0.5<hr/></td><td align="center" valign="bottom">5.0<hr/></td><td align="center" valign="bottom">9.0<hr/></td><td align="center" valign="bottom">30<hr/></td><td align="center" valign="bottom">5.1<hr/></td><td align="center" valign="bottom">2.7<hr/></td><td align="center" valign="bottom">0.0<hr/></td><td align="center" valign="bottom">5.3<hr/></td><td align="center" valign="bottom">9.0<hr/></td></tr><tr><td align="left" valign="bottom">Pain score end of RT (VAS)<hr/></td><td align="center" valign="bottom">30<hr/></td><td align="center" valign="bottom">2.4<hr/></td><td align="center" valign="bottom">2.0<hr/></td><td align="center" valign="bottom">0.0<hr/></td><td align="center" valign="bottom">2.0<hr/></td><td align="center" valign="bottom">8.0<hr/></td><td align="center" valign="bottom">30<hr/></td><td align="center" valign="bottom">3.3<hr/></td><td align="center" valign="bottom">2.5<hr/></td><td align="center" valign="bottom">0.0<hr/></td><td align="center" valign="bottom">3.3<hr/></td><td align="center" valign="bottom">9.0<hr/></td></tr><tr><td align="left" valign="bottom">Pain score after 3&#x000a0;month (VAS)<hr/></td><td align="center" valign="bottom">25<hr/></td><td align="center" valign="bottom">1.9<hr/></td><td align="center" valign="bottom">1.4<hr/></td><td align="center" valign="bottom">0.0<hr/></td><td align="center" valign="bottom">1.5<hr/></td><td align="center" valign="bottom">5.0<hr/></td><td align="center" valign="bottom">23<hr/></td><td align="center" valign="bottom">3.8<hr/></td><td align="center" valign="bottom">2.3<hr/></td><td align="center" valign="bottom">0.0<hr/></td><td align="center" valign="bottom">4.5<hr/></td><td align="center" valign="bottom">7.0<hr/></td></tr><tr><td align="left" valign="bottom">Treatment effect within groups (t2)<hr/></td><td align="center" valign="bottom">&#x000a0;<hr/></td><td align="center" valign="bottom">p&#x02009;&#x0003c;&#x02009;.001<hr/></td><td align="center" valign="bottom">&#x000a0;<hr/></td><td align="center" valign="bottom">&#x000a0;<hr/></td><td align="center" valign="bottom">&#x000a0;<hr/></td><td align="center" valign="bottom">&#x000a0;<hr/></td><td align="center" valign="bottom">&#x000a0;<hr/></td><td align="center" valign="bottom">p&#x02009;=&#x02009;0.010<hr/></td><td align="center" valign="bottom">&#x000a0;<hr/></td><td align="center" valign="bottom">&#x000a0;<hr/></td><td align="center" valign="bottom">&#x000a0;<hr/></td><td align="center" valign="bottom">&#x000a0;<hr/></td></tr><tr><td align="left" valign="bottom">Treatment effect between groups (t2)<hr/></td><td align="center" valign="bottom">&#x000a0;<hr/></td><td align="center" valign="bottom">p&#x02009;=&#x02009;0.003<hr/></td><td align="center" valign="bottom">&#x000a0;<hr/></td><td align="center" valign="bottom">&#x000a0;<hr/></td><td align="center" valign="bottom">&#x000a0;<hr/></td><td align="center" valign="bottom">&#x000a0;<hr/></td><td align="center" valign="bottom">&#x000a0;<hr/></td><td align="center" valign="bottom">&#x000a0;<hr/></td><td align="center" valign="bottom">&#x000a0;<hr/></td><td align="center" valign="bottom">&#x000a0;<hr/></td><td align="center" valign="bottom">&#x000a0;<hr/></td><td align="center" valign="bottom">&#x000a0;<hr/></td></tr><tr><td align="left" valign="bottom">No response (n, %)<hr/></td><td align="center" valign="bottom">8<hr/></td><td align="center" valign="bottom">32%<hr/></td><td align="center" valign="bottom">&#x000a0;<hr/></td><td align="center" valign="bottom">&#x000a0;<hr/></td><td align="center" valign="bottom">&#x000a0;<hr/></td><td align="center" valign="bottom">&#x000a0;<hr/></td><td align="center" valign="bottom">12<hr/></td><td colspan="2" align="center" valign="bottom">52.2%<hr/></td><td align="center" valign="bottom">&#x000a0;<hr/></td><td align="center" valign="bottom">&#x000a0;<hr/></td><td align="center" valign="bottom">&#x000a0;<hr/></td></tr><tr><td align="left" valign="bottom">Partial response (n, %)<hr/></td><td align="center" valign="bottom">5<hr/></td><td align="center" valign="bottom">20%<hr/></td><td align="center" valign="bottom">&#x000a0;<hr/></td><td align="center" valign="bottom">&#x000a0;<hr/></td><td align="center" valign="bottom">&#x000a0;<hr/></td><td align="center" valign="bottom">&#x000a0;<hr/></td><td align="center" valign="bottom">6<hr/></td><td colspan="2" align="center" valign="bottom">26.1%<hr/></td><td align="center" valign="bottom">&#x000a0;<hr/></td><td align="center" valign="bottom">&#x000a0;<hr/></td><td align="center" valign="bottom">&#x000a0;<hr/></td></tr><tr><td align="left" valign="bottom">Complete response (n, %)<hr/></td><td align="center" valign="bottom">12<hr/></td><td align="center" valign="bottom">48%<hr/></td><td align="center" valign="bottom">&#x000a0;<hr/></td><td align="center" valign="bottom">&#x000a0;<hr/></td><td align="center" valign="bottom">&#x000a0;<hr/></td><td align="center" valign="bottom">&#x000a0;<hr/></td><td align="center" valign="bottom">5<hr/></td><td colspan="2" align="center" valign="bottom">21.7%<hr/></td><td align="center" valign="bottom">&#x000a0;<hr/></td><td align="center" valign="bottom">&#x000a0;<hr/></td><td align="center" valign="bottom">&#x000a0;<hr/></td></tr><tr><td align="left">Treatment effect (t2)</td><td align="center">&#x000a0;</td><td colspan="2" align="center">p&#x02009;=&#x02009;0.158</td><td align="center">&#x000a0;</td><td align="center">&#x000a0;</td><td align="center">&#x000a0;</td><td align="center">&#x000a0;</td><td align="center">&#x000a0;</td><td align="center">&#x000a0;</td><td align="center">&#x000a0;</td><td align="center">&#x000a0;</td><td align="center">&#x000a0;</td></tr></tbody></table><table-wrap-foot><p>The &#x0201c;chair stand test&#x0201d; showed an improvement in intervention group over the course (p&#x02009;&#x0003c;&#x02009;.001), and between groups in favor to intervention group (p&#x02009;&#x0003c;&#x02009;.001). The intervention group improved in pain score (VAS, 0&#x02013;10) over the course (p&#x02009;&#x0003c;&#x02009;.001), and was significant better between groups (p&#x02009;=&#x02009;.003) after 3&#x000a0;month. The overall pain response showed no significant difference between groups (p&#x02009;=&#x02009;.158). Wilcoxon U test was used between groups, signed-rank test was used within groups. Chi-square test was measured for pain response.</p></table-wrap-foot></table-wrap><table-wrap position="float" id="T5"><label>Table 5</label><caption><p>Results of activity questionnaire of both groups</p></caption><table frame="hsides" rules="groups" border="1"><colgroup><col align="center"/><col align="center"/><col align="center"/><col align="center"/><col align="center"/><col align="center"/><col align="center"/><col align="center"/><col align="center"/><col align="center"/><col align="center"/><col align="center"/><col align="center"/><col align="center"/><col align="center"/></colgroup><thead valign="top"><tr><th align="center" valign="bottom">&#x000a0;<hr/></th><th colspan="6" align="center" valign="bottom"><bold>Intervention group</bold><hr/></th><th align="center" valign="bottom"><bold>p-value</bold><hr/></th><th colspan="6" align="center" valign="bottom"><bold>Control group (n&#x02009;=&#x02009;30)</bold><hr/></th><th align="center" valign="bottom"><bold>p-value</bold><hr/></th></tr><tr><th align="center" valign="bottom">&#x000a0;<hr/></th><th colspan="3" align="center" valign="bottom"><bold>Baseline (t0) (n&#x02009;=&#x02009;30)</bold><hr/></th><th colspan="3" align="center" valign="bottom"><bold>After 3&#x000a0;month (t2) (n&#x02009;=&#x02009;25)</bold><hr/></th><th align="center" valign="bottom">&#x000a0;<hr/></th><th colspan="3" align="center" valign="bottom"><bold>Baseline (t0) (n&#x02009;=&#x02009;30)</bold><hr/></th><th colspan="3" align="center" valign="bottom"><bold>After 3&#x000a0;month (t2) (n&#x02009;=&#x02009;23)</bold><hr/></th><th align="center" valign="bottom">&#x000a0;<hr/></th></tr><tr><th align="center"><bold>Q</bold></th><th align="center"><bold>Mean</bold></th><th align="center"><bold>Min</bold></th><th align="center"><bold>Max</bold></th><th align="center"><bold>Mean</bold></th><th align="center"><bold>Min</bold></th><th align="center"><bold>Max</bold></th><th align="center">&#x000a0;</th><th align="center"><bold>Mean</bold></th><th align="center"><bold>Min</bold></th><th align="center"><bold>Max</bold></th><th align="center"><bold>Mean</bold></th><th align="center"><bold>Min</bold></th><th align="center"><bold>Max</bold></th><th align="center">&#x000a0;</th></tr></thead><tbody valign="top"><tr><td align="center" valign="bottom">1<hr/></td><td align="center" valign="bottom">2.5<hr/></td><td align="center" valign="bottom">1.0<hr/></td><td align="center" valign="bottom">6.0<hr/></td><td align="center" valign="bottom">1.8<hr/></td><td align="center" valign="bottom">1.0<hr/></td><td align="center" valign="bottom">5.0<hr/></td><td align="center" valign="bottom">0.063<hr/></td><td align="center" valign="bottom">3.6<hr/></td><td align="center" valign="bottom">1.0<hr/></td><td align="center" valign="bottom">6.0<hr/></td><td align="center" valign="bottom">3.2<hr/></td><td align="center" valign="bottom">1.0<hr/></td><td align="center" valign="bottom">6.0<hr/></td><td align="center" valign="bottom">0.022<hr/></td></tr><tr><td align="center" valign="bottom">2<hr/></td><td align="center" valign="bottom">2.6<hr/></td><td align="center" valign="bottom">1.0<hr/></td><td align="center" valign="bottom">6.0<hr/></td><td align="center" valign="bottom">2.0<hr/></td><td align="center" valign="bottom">1.0<hr/></td><td align="center" valign="bottom">6.0<hr/></td><td align="center" valign="bottom">0.137<hr/></td><td align="center" valign="bottom">3.4<hr/></td><td align="center" valign="bottom">1.0<hr/></td><td align="center" valign="bottom">6.0<hr/></td><td align="center" valign="bottom">3.6<hr/></td><td align="center" valign="bottom">1.0<hr/></td><td align="center" valign="bottom">6.0<hr/></td><td align="center" valign="bottom">0.028<hr/></td></tr><tr><td align="center" valign="bottom">3<hr/></td><td align="center" valign="bottom">3.5<hr/></td><td align="center" valign="bottom">1.0<hr/></td><td align="center" valign="bottom">6.0<hr/></td><td align="center" valign="bottom">3.6<hr/></td><td align="center" valign="bottom">1.0<hr/></td><td align="center" valign="bottom">6.0<hr/></td><td align="center" valign="bottom">0.490<hr/></td><td align="center" valign="bottom">3.8<hr/></td><td align="center" valign="bottom">1.0<hr/></td><td align="center" valign="bottom">6.0<hr/></td><td align="center" valign="bottom">3.1<hr/></td><td align="center" valign="bottom">1.0<hr/></td><td align="center" valign="bottom">6.0<hr/></td><td align="center" valign="bottom">0.255<hr/></td></tr><tr><td align="center" valign="bottom">4<hr/></td><td align="center" valign="bottom">2.3<hr/></td><td align="center" valign="bottom">1.0<hr/></td><td align="center" valign="bottom">6.0<hr/></td><td align="center" valign="bottom">1.9<hr/></td><td align="center" valign="bottom">1.0<hr/></td><td align="center" valign="bottom">6.0<hr/></td><td align="center" valign="bottom">0.011<hr/></td><td align="center" valign="bottom">3.6<hr/></td><td align="center" valign="bottom">1.0<hr/></td><td align="center" valign="bottom">6.0<hr/></td><td align="center" valign="bottom">3.1<hr/></td><td align="center" valign="bottom">1.0<hr/></td><td align="center" valign="bottom">6.0<hr/></td><td align="center" valign="bottom">0.063<hr/></td></tr><tr><td align="center" valign="bottom">5<hr/></td><td align="center" valign="bottom">2326.7<hr/></td><td align="center" valign="bottom">100<hr/></td><td align="center" valign="bottom">5000<hr/></td><td align="center" valign="bottom">2768.0<hr/></td><td align="center" valign="bottom">100<hr/></td><td align="center" valign="bottom">5000<hr/></td><td align="center" valign="bottom">0.061<hr/></td><td align="center" valign="bottom">1430.0<hr/></td><td align="center" valign="bottom">100<hr/></td><td align="center" valign="bottom">5000<hr/></td><td align="center" valign="bottom">1882.6<hr/></td><td align="center" valign="bottom">100<hr/></td><td align="center" valign="bottom">5000<hr/></td><td align="center" valign="bottom">0.109<hr/></td></tr><tr><td align="center" valign="bottom">6<hr/></td><td align="center" valign="bottom">3.0<hr/></td><td align="center" valign="bottom">1.0<hr/></td><td align="center" valign="bottom">6.0<hr/></td><td align="center" valign="bottom">2.8<hr/></td><td align="center" valign="bottom">1.0<hr/></td><td align="center" valign="bottom">6.0<hr/></td><td align="center" valign="bottom">1.000<hr/></td><td align="center" valign="bottom">2.9<hr/></td><td align="center" valign="bottom">1.0<hr/></td><td align="center" valign="bottom">6.0<hr/></td><td align="center" valign="bottom">2.6<hr/></td><td align="center" valign="bottom">1.0<hr/></td><td align="center" valign="bottom">6.0<hr/></td><td align="center" valign="bottom">0.791<hr/></td></tr><tr><td align="center" valign="bottom">7<hr/></td><td align="center" valign="bottom">0.4<hr/></td><td align="center" valign="bottom">0.0<hr/></td><td align="center" valign="bottom">1.0<hr/></td><td align="center" valign="bottom">0.5<hr/></td><td align="center" valign="bottom">0.0<hr/></td><td align="center" valign="bottom">1.0<hr/></td><td align="center" valign="bottom">0.426<hr/></td><td align="center" valign="bottom">0.3<hr/></td><td align="center" valign="bottom">0.0<hr/></td><td align="center" valign="bottom">1.0<hr/></td><td align="center" valign="bottom">0.4<hr/></td><td align="center" valign="bottom">0.0<hr/></td><td align="center" valign="bottom">1.0<hr/></td><td align="center" valign="bottom">0.548<hr/></td></tr><tr><td align="center" valign="bottom">8<hr/></td><td align="center" valign="bottom">2466.7<hr/></td><td align="center" valign="bottom">0.0<hr/></td><td align="center" valign="bottom">10000<hr/></td><td align="center" valign="bottom">4400.0<hr/></td><td align="center" valign="bottom">0.0<hr/></td><td align="center" valign="bottom">15000<hr/></td><td align="center" valign="bottom">0.708<hr/></td><td align="center" valign="bottom">3000.0<hr/></td><td align="center" valign="bottom">0.0<hr/></td><td align="center" valign="bottom">20000<hr/></td><td align="center" valign="bottom">3347.8<hr/></td><td align="center" valign="bottom">0.0<hr/></td><td align="center" valign="bottom">20000<hr/></td><td align="center" valign="bottom">0.478<hr/></td></tr><tr><td align="center" valign="bottom">9<hr/></td><td align="center" valign="bottom">1.3<hr/></td><td align="center" valign="bottom">0.0<hr/></td><td align="center" valign="bottom">6.0<hr/></td><td align="center" valign="bottom">1.6<hr/></td><td align="center" valign="bottom">0.0<hr/></td><td align="center" valign="bottom">6.0<hr/></td><td align="center" valign="bottom">0.848<hr/></td><td align="center" valign="bottom">1.6<hr/></td><td align="center" valign="bottom">0.0<hr/></td><td align="center" valign="bottom">6.0<hr/></td><td align="center" valign="bottom">1.8<hr/></td><td align="center" valign="bottom">0.0<hr/></td><td align="center" valign="bottom">6.0<hr/></td><td align="center" valign="bottom">0.945<hr/></td></tr><tr><td align="center" valign="bottom">10<hr/></td><td align="center" valign="bottom">2.8<hr/></td><td align="center" valign="bottom">1.0<hr/></td><td align="center" valign="bottom">6.0<hr/></td><td align="center" valign="bottom">2.6<hr/></td><td align="center" valign="bottom">1.0<hr/></td><td align="center" valign="bottom">6.0<hr/></td><td align="center" valign="bottom">0.008<hr/></td><td align="center" valign="bottom">4.1<hr/></td><td align="center" valign="bottom">1.0<hr/></td><td align="center" valign="bottom">6.0<hr/></td><td align="center" valign="bottom">3.7<hr/></td><td align="center" valign="bottom">1.0<hr/></td><td align="center" valign="bottom">6.0<hr/></td><td align="center" valign="bottom">0.080<hr/></td></tr><tr><td align="center">11</td><td align="center">3.8</td><td align="center">1.0</td><td align="center">6.0</td><td align="center">3.3</td><td align="center">1.0</td><td align="center">6.0</td><td align="center">0.675</td><td align="center">4.0</td><td align="center">1.0</td><td align="center">6.0</td><td align="center">3.3</td><td align="center">1.0</td><td align="center">6.0</td><td align="center">0.974</td></tr></tbody></table></table-wrap><p>The local control of metastases under treatment was 100% in both groups. In Arm A, no progression of other metastases in the vertebral column was seen after three months, while progression was recorded in 17.4% of the patients in Arm B (n&#x02009;=&#x02009;4).</p><p>The intervention group improved in pain score (VAS, 0&#x02013;10) over the course (p&#x02009;&#x0003c;&#x02009;.001), and was significant better between groups (p&#x02009;=&#x02009;.003) after 3&#x000a0;month. The results for complete pain response and partial response were 48% and 20%, respectively, in Arm A and 21.7% and 26.1% in Arm B. The overall pain response showed no significant difference between groups (p&#x02009;=&#x02009;.158) (Table&#x000a0;
<xref ref-type="table" rid="T4">4</xref>).</p><p>The median overall survival of the intervention group was 88.6&#x000a0;months, six-month survival 90%, and twelve-month survival 83.1%. The median overall survival of the control group was 72&#x000a0;months, and six- and twelve-month survival 96.6% and 78.6%, respectively (p&#x02009;=&#x02009;.626). No statistically significant difference was observed (Figure&#x000a0;
<xref ref-type="fig" rid="F3">3</xref>). Median bone survival was 23.3&#x000a0;months in Arm A (range 2.1-52.0) and 11.2&#x000a0;months in Arm B (range 1.3-96.4) (p&#x02009;=&#x02009;.558).</p><fig id="F3" position="float"><label>Figure 3</label><caption><p>Overall survival of both arms, time in month.</p></caption><graphic xlink:href="1471-2407-14-67-3"/></fig></sec><sec sec-type="discussion"><title>Discussion</title><p>Bone metastases are a very frequent secondary diagnosis associated with an advanced tumor disease, with the vertebral column being the most frequent localization
[<xref ref-type="bibr" rid="B17">17</xref>,<xref ref-type="bibr" rid="B18">18</xref>]. Patients affected by this condition are usually immobilized, primarily due to the risk of pathological fractures and the related danger of spinal cord compression. Previous clinical studies have shown that tumor patients may profit from physical training measures during and following medical treatment
[<xref ref-type="bibr" rid="B6">6</xref>,<xref ref-type="bibr" rid="B7">7</xref>,<xref ref-type="bibr" rid="B9">9</xref>,<xref ref-type="bibr" rid="B19">19</xref>,<xref ref-type="bibr" rid="B20">20</xref>]. Patients in the intervention group felt less exhausted and less psychically stressed following the training session; moreover, the pain felt during training was less intense. The specific enhancing effects of physical exercise, however, vary according to the degree of the primary disease, the medical treatment principles, and the patient&#x02019;s current lifestyle
[<xref ref-type="bibr" rid="B5">5</xref>]. The German Association for Sports Medicine and Prevention and the German Cancer Society have published guidelines for the design of training and sports programs for tumor patients; in these guidelines, the targeted sports intervention is deemed contraindicated in patients with bone metastases
[<xref ref-type="bibr" rid="B21">21</xref>]. The promoting effects of differentiated training to support the vertebral column of patients with bone metastases have not yet been investigated. Current strength-training regimens with strong anabolic effects on muscles and bones may exert an influence in countering specific side-effects of tumor therapy, helping patients to improve their physical function
[<xref ref-type="bibr" rid="B8">8</xref>]. A training exertion between 20 and 30% of maximum power causes neither an increase nor a decrease in strength, and can be seen as corresponding with the daily load of induced muscle tensions
[<xref ref-type="bibr" rid="B22">22</xref>]. When a patient is immobilized, the muscles are exerted only to a degree not exceeding 20%, resulting in their atrophy
[<xref ref-type="bibr" rid="B22">22</xref>]. The training threshold, thus, lies at approximately 30-40% of the maximum muscle strength, above which training can have a positive effect
[<xref ref-type="bibr" rid="B22">22</xref>]. This was the level of exercise at which our training program was carried out without extra weights, although it was not possible to measure the maximum strength in these patients. In the intervention group, this training effect resulted in an increase in mobility, chair-stand test and activity questionnaire were used. The quantitative measurement of mobility for these patients was difficult, due the increased risk of pathological fracture. Therefore other methodical devices were not acceptable. We were not able to assess the strengthening of the muscles quantitatively, but this test was almost related to mobility for palliative patients. In addition mobility was evaluated in our non-validated questionnaire. The results of the activity questionnaire further emphasized the benefits attained in the intervention group as opposed to the control group. Other existing validated questionnaires had no information with respect to daily activity in patients with bone metastases, so we created questions independently which were relevant for these palliative patients. The questionnaire was not based on an existing one. However, this represented a major limitation. An adequate training duration corresponds to 20-30% of the time of muscle tension until exhaustion, and this was approximately the limit we used for the exercises
[<xref ref-type="bibr" rid="B22">22</xref>]. Regarding age and gender, there are indications of differing degrees to which muscles can be trained; in our study group, however, due to the homogeneous distribution this difference appears to be negligibly small. Lasting only a few seconds, the individual muscle-tension is kept so short that no load is exerted on the cardiovascular system, meaning that these exercises can be carried out also by patients with pre-existing internal diseases. In their review, Knols et al.
[<xref ref-type="bibr" rid="B5">5</xref>] demonstrated that the positive effects of exercise therapy vary depending on the type and stage of tumor, pharmaceutical therapy, therapeutical procedures, and patient lifestyle. In the review of the practicability it was not necessary to standardize the conditions, which is why simple-to-perform exercises were selected to form this standardized training program. On account of the raised risk of fracture, no extra weights were used and active movements of the vertebral column were avoided. As a measure to ensure an adequate training stimulus, which optimally lies at 40-50% of the maximum isometric strength with extra weights, the individual exercises were repeated a number of times, ensuring appropriate pauses between each set of exercises.</p><p>A decisive step was to initially classify the metastases as &#x0201c;stable&#x0201d; or &#x0201c;unstable&#x0201d;, which was done according to the Taneichi scores. According to Taneichi et al.
[<xref ref-type="bibr" rid="B12">12</xref>], significant risk factors included the destruction of the costovertebral articulation, the size of the tumor in the thoracic region (Th1-Th10), and the destruction of the pedicle as the main factors in the thoracolumbar and lumbar spine. Not only is the standardized assessment of the stability in clinical practice by means of a score rating of relevance when making the indication for radiotherapy, it also provides important information for decisions regarding mobility therapy. The feasibility of exercise in tumor patients has already been demonstrated by a number of studies
[<xref ref-type="bibr" rid="B9">9</xref>,<xref ref-type="bibr" rid="B10">10</xref>,<xref ref-type="bibr" rid="B19">19</xref>,<xref ref-type="bibr" rid="B20">20</xref>,<xref ref-type="bibr" rid="B23">23</xref>,<xref ref-type="bibr" rid="B24">24</xref>]. In their study Murnane et al.
[<xref ref-type="bibr" rid="B25">25</xref>] were able to show that the majority of patients wish to take physical exercise as an adjunct to RT. In our investigation, none of the patients withdrew from training or refused to take part because of the training program. Hayes et al.
[<xref ref-type="bibr" rid="B6">6</xref>] describe that physical exercise is associated with a benefit during and after tumor treatment, and indeed is even capable of reducing the impact of the side-effects of therapy and the symptoms of the underlying disease. The evidence emphasizes the effect of positive physiological and psychological benefits of mobility therapy during and after tumor therapy
[<xref ref-type="bibr" rid="B8">8</xref>].</p><p>The local three-month controls were performed in 100% in both groups; the interesting long-term results have not yet been evaluated, and the results will be presented in the near future.</p><p>The pain-reducing effect in the three-month course of the study showed a positive course in Arm A, but not significantly better. In a prospective collective group of 518 patients, Chow et al. were able to demonstrate complete and partial response rates at the 3-month follow up of 21% to 25% and 26% to 30% in RT group, respectively
[<xref ref-type="bibr" rid="B26">26</xref>]. Our results in the control group were comparable with these findings: the pain response in the intervention group was 48% and 20% in the three-month course.</p><p>There were no significant differences between the groups regarding overall survival (OS). Due to the differing tumor entities and the small number of patients involved, any comparison with other data cannot be representative. The bone survival data showed median values of 23.3 vs. 11.2&#x000a0;months; here, too, it was not possible to demonstrate a significant difference between the two groups.</p><p>The weak points of the study were the small number of subjects, the variety of primary tumors, the exclusion of the cervical spine, and the non-validated score of the activity questionnaire, purpose-made for this trial. The patients&#x02019; compliance with the training program in their home setting could naturally only be checked by reviewing the documentation forms completed by the patients themselves. The study&#x02019;s strong points comprised the classification of stability and the very first application of a physical exercise program in patients with metastases in vertebral bodies as a measure to enhance their mobility.</p></sec><sec sec-type="conclusions"><title>Conclusions</title><p>In this group of patients we were able to show that guided isometric training of the paravertebral muscles can be safely practiced in palliative patients with stable bone metastases of the vertebral column, improving their pain score and mobility. Large controlled trials are necessary to confirm these findings.</p></sec><sec><title>Competing interests</title><p>The authors declare that they have no competing interests.</p></sec><sec><title>Authors&#x02019; contributions</title><p>HR and JD developed and planned this trial. TB is responsible for statistical considerations/basis of the analysis. GO, MA, and TW estimated the stability of bone metastases. HR, SR, MH, DH, and IS performed the examinations and RT supervisions. HR and AG made the data collection. HR and FN performed the physical exercise. All authors read and approved the final manuscript.</p></sec><sec><title>Pre-publication history</title><p>The pre-publication history for this paper can be accessed here:</p><p><ext-link ext-link-type="uri" xlink:href="http://www.biomedcentral.com/1471-2407/14/67/prepub">http://www.biomedcentral.com/1471-2407/14/67/prepub</ext-link></p></sec></body><back><sec><title>Acknowledgements</title><p>The authors thank all of the study participants for their great effort. We would also like to thank our staff of the trial research office, especially Alexandros Gioules and our staff of physiotherapy, especially Friedbert von Nettelbladt for their great work.</p></sec><ref-list><ref id="B1"><mixed-citation publication-type="journal"><name><surname>Coleman</surname><given-names>RE</given-names></name><article-title>Metastatic bone disease: Clinical features, pathophysiology and treatment strategies</article-title><source>Cancer Treat Rev</source><year>2001</year><volume>27</volume><fpage>165</fpage><lpage>176</lpage><pub-id pub-id-type="doi">10.1053/ctrv.2000.0210</pub-id><pub-id pub-id-type="pmid">11417967</pub-id></mixed-citation></ref><ref id="B2"><mixed-citation publication-type="journal"><name><surname>Harrington</surname><given-names>KD</given-names></name><article-title>Orthopedic surgical management of skeletal complications of malignancy</article-title><source>Cancer</source><year>1997</year><volume>80</volume><issue>8</issue><fpage>1614</fpage><lpage>1627</lpage><pub-id pub-id-type="pmid">9362429</pub-id></mixed-citation></ref><ref id="B3"><mixed-citation publication-type="journal"><name><surname>Shaw</surname><given-names>B</given-names></name><name><surname>Mansfield</surname><given-names>FL</given-names></name><name><surname>Borges</surname><given-names>L</given-names></name><article-title>One-stage posterolateral decompression and stabilization for primary and metastatic vertebral tumors in the thoracic and lumbar spine</article-title><source>J Neurosurg</source><year>1989</year><volume>70</volume><fpage>405</fpage><lpage>410</lpage><pub-id pub-id-type="doi">10.3171/jns.1989.70.3.0405</pub-id><pub-id pub-id-type="pmid">2915247</pub-id></mixed-citation></ref><ref id="B4"><mixed-citation publication-type="journal"><name><surname>Lutz</surname><given-names>S</given-names></name><name><surname>Berk</surname><given-names>L</given-names></name><name><surname>Chang</surname><given-names>E</given-names></name><etal/><article-title>Palliative radiotherapy for bone metastases: an ASTRO evidence-based guideline. American Society for Radiation Oncology (ASTRO)</article-title><source>Int J Radiat Oncol Biol Phys</source><year>2011</year><volume>79</volume><issue>4</issue><fpage>965</fpage><lpage>976</lpage><comment>15</comment><pub-id pub-id-type="doi">10.1016/j.ijrobp.2010.11.026</pub-id><pub-id pub-id-type="pmid">21277118</pub-id></mixed-citation></ref><ref id="B5"><mixed-citation publication-type="journal"><name><surname>Knols</surname><given-names>R</given-names></name><name><surname>Aaronson</surname><given-names>NK</given-names></name><name><surname>Uebelhart</surname><given-names>D</given-names></name><etal/><article-title>Physical exercise in cancer patients during and after medical treatment: A systemic review of randomized and controlled clinical trials</article-title><source>J Clin Oncol</source><year>2005</year><volume>23</volume><fpage>3830</fpage><lpage>3842</lpage><pub-id pub-id-type="doi">10.1200/JCO.2005.02.148</pub-id><pub-id pub-id-type="pmid">15923576</pub-id></mixed-citation></ref><ref id="B6"><mixed-citation publication-type="journal"><name><surname>Hayes</surname><given-names>S</given-names></name><name><surname>Spence</surname><given-names>R</given-names></name><name><surname>Galvao</surname><given-names>D</given-names></name><etal/><article-title>Australian association for exercise and sport science potion stand: optimising cancer outcomes through exercise</article-title><source>J Sci Med Sport</source><year>2009</year><volume>12</volume><fpage>428</fpage><lpage>434</lpage><pub-id pub-id-type="doi">10.1016/j.jsams.2009.03.002</pub-id><pub-id pub-id-type="pmid">19428291</pub-id></mixed-citation></ref><ref id="B7"><mixed-citation publication-type="journal"><name><surname>Jacobsen</surname><given-names>P</given-names></name><name><surname>Donovan</surname><given-names>K</given-names></name><name><surname>Vadaparampil</surname><given-names>S</given-names></name><etal/><article-title>Systemic review and meta-analysis of psychological and activity-based interventions for cancer-related fatigue</article-title><source>Health Psychol</source><year>2007</year><volume>26</volume><fpage>660</fpage><lpage>667</lpage><pub-id pub-id-type="pmid">18020836</pub-id></mixed-citation></ref><ref id="B8"><mixed-citation publication-type="journal"><name><surname>Galvao</surname><given-names>DA</given-names></name><name><surname>Newton</surname><given-names>RU</given-names></name><article-title>Review of exercise intervention studies in cancer patients</article-title><source>J Clin Oncol</source><year>2005</year><volume>23</volume><fpage>899</fpage><lpage>909</lpage><pub-id pub-id-type="doi">10.1200/JCO.2005.06.085</pub-id><pub-id pub-id-type="pmid">15681536</pub-id></mixed-citation></ref><ref id="B9"><mixed-citation publication-type="journal"><name><surname>Cheville</surname><given-names>AL</given-names></name><name><surname>Girardi</surname><given-names>J</given-names></name><name><surname>Clark</surname><given-names>MM</given-names></name><etal/><article-title>Therapeutic exercise during outpatient radiation therapy for advanced cancer</article-title><source>Am J Phys Med Rehabil</source><year>2010</year><volume>89</volume><fpage>611</fpage><lpage>619</lpage><pub-id pub-id-type="doi">10.1097/PHM.0b013e3181d3e782</pub-id><pub-id pub-id-type="pmid">20531162</pub-id></mixed-citation></ref><ref id="B10"><mixed-citation publication-type="journal"><name><surname>Mustian</surname><given-names>KM</given-names></name><name><surname>Peppone</surname><given-names>L</given-names></name><name><surname>Darling</surname><given-names>TV</given-names></name><etal/><article-title>A 4-week home-based aerobic and resistance exercise program during radiation therapy: a pilot randomized clinical trial</article-title><source>J Support Oncol</source><year>2009</year><volume>7</volume><issue>5</issue><fpage>158</fpage><lpage>167</lpage><pub-id pub-id-type="pmid">19831159</pub-id></mixed-citation></ref><ref id="B11"><mixed-citation publication-type="book"><name><surname>Karnofsky</surname><given-names>DA</given-names></name><name><surname>Burchenal</surname><given-names>JH</given-names></name><person-group person-group-type="editor">MacLeod CM</person-group><article-title>The clinical evaluation of chemotherapeutic agents in cancer</article-title><source>Evaluation of Chemotherapeutic Agents</source><year>1949</year><publisher-name>New York: Columbia Univ Press</publisher-name><fpage>191</fpage><lpage>205</lpage></mixed-citation></ref><ref id="B12"><mixed-citation publication-type="journal"><name><surname>Taneichi</surname><given-names>H</given-names></name><name><surname>Kaneda</surname><given-names>K</given-names></name><name><surname>Takeda</surname><given-names>N</given-names></name><etal/><article-title>Risk factors and probability of vertebral body collapse in metastases of the thoracic and lumbar spine</article-title><source>Spine</source><year>1997</year><volume>22</volume><fpage>239</fpage><lpage>245</lpage><pub-id pub-id-type="doi">10.1097/00007632-199702010-00002</pub-id><pub-id pub-id-type="pmid">9051884</pub-id></mixed-citation></ref><ref id="B13"><mixed-citation publication-type="journal"><name><surname>Peng</surname><given-names>SM</given-names></name><name><surname>Koo</surname><given-names>M</given-names></name><name><surname>Yu</surname><given-names>ZR</given-names></name><article-title>Effects of music and essential oil inhalation on cardiac autonomic balance in healthy individuals</article-title><source>J Altern Complement Med</source><year>2009</year><volume>15</volume><issue>1</issue><fpage>53</fpage><lpage>57</lpage><pub-id pub-id-type="doi">10.1089/acm.2008.0243</pub-id><pub-id pub-id-type="pmid">19769477</pub-id></mixed-citation></ref><ref id="B14"><mixed-citation publication-type="journal"><name><surname>Rief</surname><given-names>H</given-names></name><name><surname>Jensen</surname><given-names>AD</given-names></name><name><surname>Bruckner</surname><given-names>T</given-names></name><name><surname>Herfarth</surname><given-names>K</given-names></name><name><surname>Debus</surname><given-names>J</given-names></name><article-title>Isometric muscle training of the spine musculature in patients with spinal bony metastases under radiation therapy</article-title><source>BMC Cancer</source><year>2011</year><volume>11</volume><fpage>482</fpage><pub-id pub-id-type="doi">10.1186/1471-2407-11-482</pub-id><pub-id pub-id-type="pmid">22070722</pub-id></mixed-citation></ref><ref id="B15"><mixed-citation publication-type="journal"><name><surname>Jones</surname><given-names>CJ</given-names></name><name><surname>Rikli</surname><given-names>RE</given-names></name><name><surname>Beam</surname><given-names>WC</given-names></name><article-title>A 30-s chair-stand test to measure lower body strength in community-residing older adults</article-title><source>J Aging Physical Activity</source><year>2000</year><volume>8</volume><fpage>85</fpage></mixed-citation></ref><ref id="B16"><mixed-citation publication-type="journal"><name><surname>Chow</surname><given-names>E</given-names></name><name><surname>Hoskin</surname><given-names>P</given-names></name><name><surname>Mitera</surname><given-names>G</given-names></name><etal/><article-title>Update of the international concensus on palliative radiotherapy endpoints for future clinical trials in bone metastases</article-title><source>Int J Radiation Oncol Biol Pys</source><year>2012</year><volume>82</volume><issue>5</issue><fpage>1730</fpage><lpage>1737</lpage><pub-id pub-id-type="doi">10.1016/j.ijrobp.2011.02.008</pub-id></mixed-citation></ref><ref id="B17"><mixed-citation publication-type="journal"><name><surname>Janjan</surname><given-names>N</given-names></name><name><surname>Lutz</surname><given-names>ST</given-names></name><name><surname>Bedwinek</surname><given-names>JM</given-names></name><name><surname>Hartsell</surname><given-names>WF</given-names></name><name><surname>Ng</surname><given-names>A</given-names></name><name><surname>Pieters</surname><given-names>RS</given-names><suffix>Jr</suffix></name><name><surname>Ratanatharathorn</surname><given-names>V</given-names></name><name><surname>Silberstein</surname><given-names>EB</given-names></name><name><surname>Taub</surname><given-names>RJ</given-names></name><name><surname>Yasko</surname><given-names>AW</given-names></name><name><surname>Rettenmaier</surname><given-names>A</given-names></name><article-title>Therapeutic guidelines for the treatment of bone metastasis: a report from the American College of Radiology Appropriateness Criteria Expert Panel on Radiation Oncology</article-title><source>J Palliat Med</source><year>2009</year><volume>12</volume><fpage>417</fpage><lpage>426</lpage><pub-id pub-id-type="doi">10.1089/jpm.2009.9633</pub-id><pub-id pub-id-type="pmid">19416037</pub-id></mixed-citation></ref><ref id="B18"><mixed-citation publication-type="journal"><name><surname>Coleman</surname><given-names>RE</given-names></name><article-title>Clinical features of metastatic bone disease and risk of skeletal morbidity</article-title><source>Clin Cancer Res</source><year>2006</year><volume>12</volume><fpage>6243</fpage><lpage>6249</lpage><pub-id pub-id-type="doi">10.1158/1078-0432.CCR-06-0931</pub-id></mixed-citation></ref><ref id="B19"><mixed-citation publication-type="journal"><name><surname>Maddocks</surname><given-names>M</given-names></name><name><surname>Mockett</surname><given-names>S</given-names></name><name><surname>Wilcock</surname><given-names>A</given-names></name><article-title>Is exercise an acceptable and practical therapy for people with or cured of cancer? A systemic review</article-title><source>Cancer Treat Rev</source><year>2009</year><volume>35</volume><issue>4</issue><fpage>383</fpage><lpage>390</lpage><pub-id pub-id-type="doi">10.1016/j.ctrv.2008.11.008</pub-id><pub-id pub-id-type="pmid">19131171</pub-id></mixed-citation></ref><ref id="B20"><mixed-citation publication-type="journal"><name><surname>Stevinson</surname><given-names>C</given-names></name><name><surname>Fox</surname><given-names>K</given-names></name><article-title>Feasibility of an exercise rehabilitation programme for cancer patients</article-title><source>Eur J Cancer Care</source><year>2006</year><volume>15</volume><fpage>386</fpage><lpage>396</lpage><pub-id pub-id-type="doi">10.1111/j.1365-2354.2006.00677.x</pub-id></mixed-citation></ref><ref id="B21"><mixed-citation publication-type="journal"><collab>German Cancer Association</collab><article-title>Guidelines for sports medicine and prevention, supportive medicine and rehabilitation neoplastic disease part II</article-title><source>Forum</source><year>2011</year><volume>5</volume><fpage>9</fpage><lpage>12</lpage></mixed-citation></ref><ref id="B22"><mixed-citation publication-type="book"><name><surname>Hettinger</surname><given-names>T</given-names></name><source>Isometric muscle training</source><year>1994</year><edition>6</edition><publisher-name>Landsberg am Lech: Ecomed</publisher-name></mixed-citation></ref><ref id="B23"><mixed-citation publication-type="journal"><name><surname>Nikander</surname><given-names>R</given-names></name><name><surname>Siev&#x000e4;nen</surname><given-names>H</given-names></name><name><surname>Ojala</surname><given-names>K</given-names></name><etal/><article-title>Effect of a vigorous aerobic regimen on physical performance in breast cancer patients &#x02013;a randomized controlled pilot trial</article-title><source>Acta Oncol</source><year>2007</year><volume>46</volume><fpage>181</fpage><lpage>186</lpage><pub-id pub-id-type="doi">10.1080/02841860600833145</pub-id><pub-id pub-id-type="pmid">17453366</pub-id></mixed-citation></ref><ref id="B24"><mixed-citation publication-type="journal"><name><surname>Segal</surname><given-names>RJ</given-names></name><name><surname>Reid</surname><given-names>RD</given-names></name><name><surname>Courneya</surname><given-names>KS</given-names></name><etal/><article-title>Randomized controlled trial of resistance or aerobic exercise in men receiving radiation therapy for prostate cancer</article-title><source>J Clin Oncol</source><year>2009</year><volume>27</volume><fpage>344</fpage><lpage>351</lpage><pub-id pub-id-type="pmid">19064985</pub-id></mixed-citation></ref><ref id="B25"><mixed-citation publication-type="journal"><name><surname>Murnane</surname><given-names>A</given-names></name><name><surname>Geary</surname><given-names>B</given-names></name><name><surname>Milne</surname><given-names>D</given-names></name><article-title>The exercise programming preferences and activity levels of cancer patients undergoing radiotherapy treatment</article-title><source>Support Care Cancer</source><year>2012</year><volume>20</volume><issue>5</issue><fpage>957</fpage><lpage>962</lpage><pub-id pub-id-type="doi">10.1007/s00520-011-1167-z</pub-id><pub-id pub-id-type="pmid">21523349</pub-id></mixed-citation></ref><ref id="B26"><mixed-citation publication-type="journal"><name><surname>Chow</surname><given-names>E</given-names></name><name><surname>Davis</surname><given-names>L</given-names></name><name><surname>Holden</surname><given-names>L</given-names></name><etal/><article-title>A comparison of radiotherapy outcomes of bone metastases employing international concensus endpoints and traditional endpoints</article-title><source>Support Cancer Ther</source><year>2004</year><volume>1</volume><fpage>173</fpage><lpage>178</lpage><pub-id pub-id-type="doi">10.3816/SCT.2004.n.009</pub-id></mixed-citation></ref></ref-list></back></article>